cassava7
Senior Member (Voting Rights)
Reviewer 2, Jose Alegre-Martin (who heads a CFS clinic in Barcelona, Spain), was kind, to say the least:
And so was reviewer 1, Lily Chu, who is vice-president of the IACFS/ME — she mostly asked for clarifications and adding a part on the strengths and limitations of the study.
Unfortunately, even though the paper was published in a special issue dubbed “Issue Anticoagulants and Antiplatelet Drugs”, neither reviewer commented on the technical aspects of the assay or on the pathophysiological hypothesis proposed by the authors. Peer review, of which there was only one round, essentially amounted to a free pass.
https://www.mdpi.com/1424-8247/15/8/931/review_report
Excellent working hypothesis
I think that the n should be increased and that other groups replicated the results.
In this patients with CFS and coagulation disorders, you have observed some thrombotic phenomen ?
And another serious question, would have to be anticoagulation and antiaggregation
And so was reviewer 1, Lily Chu, who is vice-president of the IACFS/ME — she mostly asked for clarifications and adding a part on the strengths and limitations of the study.
Unfortunately, even though the paper was published in a special issue dubbed “Issue Anticoagulants and Antiplatelet Drugs”, neither reviewer commented on the technical aspects of the assay or on the pathophysiological hypothesis proposed by the authors. Peer review, of which there was only one round, essentially amounted to a free pass.
https://www.mdpi.com/1424-8247/15/8/931/review_report